Analysis Kinetics of IBI319 for PD-1 by BLI (CAT#: STEM-MB-0287-CJ)

Introduction

A protein found on T cells (a type of immune cell) that helps keep the body's immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells. Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1.In addition, PD-1 expression on naïve T cells is induced upon TCR activation. This transient expression decreases in absence of TCR signaling but is maintained upon chronic activation with a persisting epitope target such as in chronic viral infections and in cancer.

IBI 319 is a bispecific monoclonal antibody, being developed by Innovent Biologics in collaboration with Eli Lilly and Company for the treatment of cancers. And IBI319 was designed as a fully humanised IgG1 molecule comprising a bivalent Fab fragment that bound to PD-1 and CD137 separately.